Insights
Why President Trump’s generic drug tariffs are unlikely to fix America’s supply problem
13 August 2026
America’s dependence on foreign generic manufacturing is a real national security and supply concern. The vast majority of drug shortages in the U.S. are generics and shortages have increasingly burdened pharmacies across the country and disrupted care for the patients who rely on them, particularly those with chronic pain and cancer.
But President Trump’s most recent policy is unlikely to fix that problem. It’s far more likely to make American medicine cabinets less reliable, not more.
What the first EU JCA reveals about assessing precision oncology
28 July 2026
We explore how the first JCA provides insights into the longstanding methodological challenge of evidence generation and comparative assessment for precision medicine.
What is a life worth in climate policy? It depends on who you ask
22 July 2026
The ECOnomic Evaluation for Climate Action (ECO-CHICA) consensus guidance is now on SSRN, with the scoping review and methodological deep dives available alongside it. Here is what they say, and why the question in the title is harder than it looks.
Around the World in HTAs: Spain – Closer than ever, but not quite yet
8 July 2026
Spain has introduced its first national legal framework for health technology assessment (HTA) through Royal Decree 415/2026. It is a significant step forward, but the system is still being built.
How long are patients WAITing for new treatments?
2 July 2026
The latest EFPIA Patients W.A.I.T. Indicator 2025 Survey shows that patients across Europe are waiting longer for access to new medicines, with major differences between countries. Here we explain how to interpret the W.A.I.T indicators.
Around the world in HTAs: Abu Dhabi – Advancing HTA and value-based healthcare in the UAE
1 July 2026
Abu Dhabi is taking important steps to strengthen the use of HTA in healthcare decision-making, with the publication of its HTA guidelines in 2025 marking an important milestone.
Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate
25 June 2026
Much of the Most-Favoured-Nation debate asks whether the United States can persuade other countries to pay more for medicines. Germany is the market where that question is hardest to answer and where it matters most.
The cost of inaction on LDL cholesterol
24 June 2026
This Insight is based on the WHA79 panel discussion “Lowering Cholesterol, Increasing Impact: The Case for Earlier Action to Address the CV Epidemic”, co-organised by OHE and MSD, at the World Health Assembly in Geneva, May 2026.
One Europe, one assessment? Unpacking the European Joint Clinical Assessment
28 May 2026
As the first EU Joint Clinical Assessment reports approach, national HTA systems across Europe are already adapting to a new era of coordinated clinical evaluation.